

Web appendix

Sensitivity analysis (studies are weighted by their quality score)

Arm characteristics	Coefficient [95% Confidence Interval]	p value
RCT (Ref = observational)	0,51 [0,30 to 0,87]	0,013
Treatment (Ref= placebo)		
SSRI	1,22 [0,83 to 1,79]	0,3
SNRI	1,95 [1,13 to 3,39]	0,017
IP	1,84 [1,20 to 2,85]	0,006
Other classes	1,54 [1,04 to 2,29]	0,032
All classes	1,18 [0,80 to 1,75]	0,41
Previous antidepressant resistance (Ref=no)	0,71 [0,20 to 2,60]	0,61
Patient type (Ref= outpatient)		
Out and inpatient	1,23 [0,60 to 2,53]	0,571
Inpatient	2,17 [0,90 to 5,22]	0,084
Age classes (Ref= children and adolescent)		
Adults	0,2 [0,06 to 0,66]	0,008
Both	3,84 [0,93 to 15,86]	0,063
Diagnosis (Ref= unipolar)		
Bipolar disorder	21,54 [7,93 to 58,51]	<0,001
Unipolar and bipolar	1,61 [0,46 to 5,62]	0,46
Year of study	0,98 [0,95 to 1,01]	0,14
Study duration	1,02 [0,99 to 1,04]	0,26
Proportion of women	1 [0,98 to 1,02]	0,78

SSRI= Selective Serotonin Reuptake Inhibitor

SNRI=Serotonin-Norepinephrine Reuptake Inhibitors

IP= Imipraminics

References included in quantitative synthesis

- Altshuler LL, Suppes T, Black DO, Nolen WA, Leverich G, Keck PE Jr, Frye MA, Kupka R, McElroy SL, Grunze H, Kitchen CMR, Post R: Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006; 163:313–315
- Amsterdam J: Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol 1998; 18:414–417
- Amsterdam JD, Shults J, Brunswick DJ, Hundert M: Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate. Bipolar Disord 2004; 6:75–81
- Amsterdam JD, Shults J: Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction. J Affect Disord 2005; 87:121–130
- Amsterdam JD, Shults J: Comparison of Short-Term Venlafaxine Versus Lithium Monotherapy for Bipolar II Major Depressive Episode: A Randomized Open-Label Study. Journal of Clinical Psychopharmacology 2008; 28:171–181
- Amsterdam JD, Garcia-España F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Schweizer E, Beasley C: Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin

- Psychopharmacol 1998; 18:435–440
7. Baldassano CF, Sachs GS, Stoll AL, Lafer B, Truman CJ: Paroxetine for bipolar depression: Outcome in patients failing prior antidepressant trials [Internet]. Depression 1995; 3:182–186
 8. Bauer M, Zaninelli R, Müller-Oerlinghausen B, Meister W: Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J Clin Psychopharmacol 1999; 19:164–171
 9. Baumhackl U, Biziére K, Fischbach R, Geretsegger C, Hebenstreit G, Radmayr E, Stabl M: Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study. Br J Psychiatry Suppl 1989; 78–83
 10. Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del Zompo M: A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand 1993; 88:434–439
 11. Bottlender R, Rudolf D, Strauss A, Möller HJ: Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression. Eur Arch Psychiatry Clin Neurosci 1998; 248:296–300
 12. Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J: Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299:901–913
 13. Brown EB, McElroy SL, Keck PE Jr, Deldar A, Adams DH, Tohen M, Williamson DJ: A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67:1025–1033
 14. Browne MW, Kreeger LC, Kazamias NG: A clinical trial of amitriptyline in depressive patients. Br J Psychiatry 1963; 109:692–694
 15. Cohn JB, Collins G, Ashbrook E, Wernicke JF: A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4:313–322
 16. Danish University Antidepressant group: Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord 1990; 18:289–299
 17. De Wilde JE, Doogan DP: Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord 1982; 4:249–259
 18. Dunner DL, D'Souza DN, Kajdasz DK, Detke MJ, Russell JM: Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression. J Affect Disord 2005; 87:115–119
 19. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch. Gen. Psychiatry 1997; 54:1031–1037
 20. Emslie G, Kratochvil C, Vitiello B, Silva S, Mayes T, McNulty S, Weller E, Waslick B, Casat C, Walkup J, Pathak S, Rohde P, Posner K, March J, Columbia Suicidality Classification Group, TADS Team: Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry 2006; 45:1440–1455
 21. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG: Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41:1205–1215
 22. Erfurth A, Michael N, Stadtland C, Arolt V: Bupropion as add-on strategy in difficult-to-treat bipolar

- depressive patients. *Neuropsychobiology* 2002; 45 Suppl 1:33–36
- 23. Fogelson DL, Bystritsky A, Pasnau R: Bupropion in the treatment of bipolar disorders: the same old story? *J Clin Psychiatry* 1992; 53:443–446
 - 24. Fonseca M, Soares JC, Hatch JP, Santin AP, Kapczinski F: An open trial of adjunctive escitalopram in bipolar depression. *J Clin Psychiatry* 2006; 67:81–86
 - 25. Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M: Antidepressant-induced mania in bipolar patients: identification of risk factors. *J Clin Psychiatry* 2001; 62:249–255
 - 26. Himmelhoch JM, Thase ME, Mallinger AG, Houck P: Tranylcypromine versus imipramine in anergic bipolar depression. *Am J Psychiatry* 1991; 148:910–916
 - 27. Hohn R, Gross GM, Gross M, Lasagna L: A double-blind comparison of placebo and imipramine in the treatment of depressed patients in a state hospital. *J Psychiatr Res* 1961; 1:76–91
 - 28. Jann MW, Bitar AH, Rao A: Lithium prophylaxis of tricyclic-antidepressant-induced mania in bipolar patients. *Am J Psychiatry* 1982; 139:683–684
 - 29. Joffe RT, MacQueen GM, Marriott M, Robb J, Begin H, Young LT: Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. *Acta Psychiatr Scand* 2002; 105:427–430
 - 30. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP: Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. *J Am Acad Child Adolesc Psychiatry* 2001; 40:762–772
 - 31. Keup W, Apolito A, Olinger L, Schwartz M, Yachnes E: Inpatient treatment of depressive states with tofranil (imipramine hydrochloride). *Am J Psychiatry* 1959; 116:257–258
 - 32. Klein DF: Chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders. *Can Psychiatr Assoc J* 1966; 11 Suppl:146–149
 - 33. Kupfer DJ, Carpenter LL, Frank E: Possible role of antidepressants in precipitating mania and hypomania in recurrent depression. *Am J Psychiatry* 1988; 145:804–808
 - 34. Kupfer DJ, Chengappa KN, Gelenberg AJ, Hirschfeld RM, Goldberg JF, Sachs GS, Grochocinski VJ, Houck PR, Kolar AB: Citalopram as adjunctive therapy in bipolar depression. *J Clin Psychiatry* 2001; 62:985–990
 - 35. Leyberg JT, Denmark JC: The treatment of depressive states with imipramine hydrochloride (tofranil). *J Ment Sci* 1959; 105:1123–1126
 - 36. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D: Age effects on antidepressant-induced manic conversion. *Arch Pediatr Adolesc Med* 2004; 158:773–780
 - 37. McConville BJ, Minnery KL, Sorter MT, West SA, Friedman LM, Christian K: An open study of the effects of sertraline on adolescent major depression. *J Child Adolesc Psychopharmacol* 1996; 6:41–51
 - 38. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH, EMBOLDEN II (Trial D1447C00134) Investigators: A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). *J Clin Psychiatry* 2010; 71:163–174
 - 39. Nasrallah HA, Lyskowksi J, Schroeder D: TCA-induced mania: differences between switchers and nonswitchers. *Biol. Psychiatry* 1982; 17:271–274

40. Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD: Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. *Am J Psychiatry* 2001; 158:906–912
41. Normann C, Hummel B, Schärer LO, Hörn M, Grunze H, Walden J: Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. *J Clin Psychiatry* 2002; 63:337–344
42. Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, Suppes T, McElroy S, Keck PE, Denicoff KD, Grunze H, Walden J, Kitchen CMR, Mintz J: Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. *Br J Psychiatry* 2006; 189:124–131
43. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME: Effectiveness of adjunctive antidepressant treatment for bipolar depression. *N. Engl. J. Med.* 2007; 356:1711–1722
44. Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF: A double-blind trial of bupropion versus desipramine for bipolar depression. *J Clin Psychiatry* 1994; 55:391–393
45. Schaffer A, Zuker P, Levitt A: Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. *J Affect Disord* 2006; 96:95–99
46. Shelton RC, Stahl SM: Risperidone and paroxetine given singly and in combination for bipolar depression. *J Clin Psychiatry* 2004; 65:1715–1719
47. Shirazi E, Alaghband-Rad J: An open trial of citalopram in children and adolescents with depression. *J Child Adolesc Psychopharmacol* 2005; 15:233–239
48. Silverstone T: Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. *Acta Psychiatr Scand* 2001; 104:104–109
49. Simpson SG, DePaulo JR: Fluoxetine treatment of bipolar II depression. *J Clin Psychopharmacol* 1991; 11:52–54
50. Skarbek A: Trial of amitriptyline in chronic depression. *Dis Nerv Syst* 1963; 24:115–119
51. Stoner SC, Worrel JA, Vlach D, Jones MT, Ramlatchman LV: Retrospective analysis of serum valproate levels and need for an antidepressant drug. *Pharmacotherapy* 2001; 21:850–854
52. Tierney E, Joshi PT, Llinas JF, Rosenberg LA, Riddle MA: Sertraline for Major Depression in Children and Adolescents: Preliminary Clinical Experience. *Journal of Child and Adolescent Psychopharmacology* 1995; 5:13–27
53. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tolleson GD, Breier A: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. *Arch. Gen. Psychiatry* 2003; 60:1079–1088
54. Truman CJ, Goldberg JF, Ghaemi SN, Baldassano CF, Wisniewski SR, Dennehy EB, Thase ME, Sachs GS: Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *J Clin Psychiatry* 2007; 68:1472–1479
55. van Scheyen JD, van Kammen DP: Clomipramine-induced mania in unipolar depression. *Arch. Gen. Psychiatry* 1979; 36:560–565
56. Vieta E, Martínez-Aráñ A, Goikolea JM, Torrent C, Colom F, Benabarre A, Reinares M: A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. *J Clin Psychiatry* 2002; 63:508–512

57. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I: Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. *Am J Psychiatry* 2000; 157:124–126